Reply

We thank Papamichail and Cheifetz for their comments about our manuscript “Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection.”1 Overall we agree with the comments and limitations about the original article outlined in the letter that we discussed in the main paper. Infections related to Crohn’s disease were excluded t o focus on infection related to therapeutic immunosuppression. That said only 2 patients presented such complications during the follow-up period, both with trough level of infliximab greater than 12 mg/L.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letters to the Editor Source Type: research